2026

Systematic evaluation of neoepitope predictions challenges clinically observed T-cell responses and their impact on immune evasion.
Zaghla, Badeel Kh Q. ORCID: https://orcid.org/0009-0002-2675-8859, Safürek, Zuhal ORCID: https://orcid.org/0009-0004-8412-5069, Gröger, Daniela, Mecklenbräuker, Shima, Lingstädt, Nina-Sophie, Popp, Oliver ORCID: https://orcid.org/0000-0001-6240-4666, Spengler, Johanna, Haji, Mohamed, Montesion, Meagan, Albacker, Lee A., Mertins, Philipp ORCID: https://orcid.org/0000-0002-2245-528X and Klatt, Martin G. ORCID: https://orcid.org/0000-0001-8703-7305
Journal for ImmunoTherapy of Cancer 14 (1): e013271. January 2026

2025

Clonally expanded effector CD4(+) cytotoxic T lymphocytes are associated with severe neurological adverse events after immune checkpoint inhibitor therapy.
Giguelay, Ambre Manon ORCID: https://orcid.org/0000-0003-0417-1109, Maschmeyer, Patrick ORCID: https://orcid.org/0000-0002-1705-5302, Müller-Jensen, Leonie ORCID: https://orcid.org/0000-0002-6388-9375, Schinke, Christian, Maierhof, Smilla K., Nambiar, Natasha ORCID: https://orcid.org/0009-0004-3538-8081, Meyer, Manpreet ORCID: https://orcid.org/0009-0004-5700-8529, Huehnchen, Petra ORCID: https://orcid.org/0000-0002-6825-7270, Boehmerle, Wolfgang ORCID: https://orcid.org/0000-0001-7195-3894, Endres, Matthias ORCID: https://orcid.org/0000-0001-6520-3720, Knauss, Samuel and Ludwig, Leif S. ORCID: https://orcid.org/0000-0002-2916-2164
Journal for ImmunoTherapy of Cancer 13 (10): e012350. 30 October 2025

Enhanced mutanome analysis towards the induction of neoepitope-reactive T-cell responses for personalized immunotherapy of pancreatic cancer.
Volkmar, M., Hoser, D., Lauenstein, C., Rebmann, J., Hotz-Wagenblatt, A., Rieger, J., Poschke, I. ORCID: https://orcid.org/0000-0002-4387-5566, Becker, J.P., Riemer, A.B., Sprick, M., Trumpp, A., Strobel, O., Blankenstein, T. ORCID: https://orcid.org/0000-0002-3357-4321, Willimsky, G. ORCID: https://orcid.org/0000-0002-9693-948X and Offringa, R. ORCID: https://orcid.org/0000-0001-6310-1026
Journal for ImmunoTherapy of Cancer 13 (6): e011802. June 2025

Selection of therapeutically effective T-cell receptors from the diverse tumor-bearing repertoire.
Rosenberger, L., Hansmann, L. ORCID: https://orcid.org/0000-0003-3790-0128, Anastasopoulou, V., Wolf, S.P. ORCID: https://orcid.org/0009-0008-2723-695X, Drousch, K., Moewes, C., Feng, X., Cao, G., Huang, J. ORCID: https://orcid.org/0000-0003-0271-4384, Yew, P.Y., Strønen, E. ORCID: https://orcid.org/0000-0001-9314-9389, Kato, T., Saligrama, N., Olweus, J., Nakamura, Y., Willimsky, G. ORCID: https://orcid.org/0000-0002-9693-948X, Blankenstein, T. ORCID: https://orcid.org/0000-0002-3357-4321, Schreiber, H. and Leisegang, M. ORCID: https://orcid.org/0000-0003-3692-7142
Journal for ImmunoTherapy of Cancer 13 (5): e011351. 2 May 2025

Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-Hodgkin's lymphoma.
Junkuhn, C., Schiele, P., Walter, A.L., Hamm, F., Obermayer, B. ORCID: https://orcid.org/0000-0002-9116-630X, Busch, D., Stroux, A., Frick, M., Penack, O., Damm, F., Polansky, J., Bullinger, L. ORCID: https://orcid.org/0000-0002-5890-5510, Künkele, A., Frentsch, M. and Na, I.K. ORCID: https://orcid.org/0000-0001-9902-5424
Journal for ImmunoTherapy of Cancer 13 (4): e010709. April 2025

2024

CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation.
Eitler, J. ORCID: https://orcid.org/0000-0002-3175-2438, Rackwitz, W., Wotschel, N., Gudipati, V., Murali Shankar, N., Sidorenkova, A., Huppa, J.B. ORCID: https://orcid.org/0000-0003-2634-8198, Ortiz-Montero, P., Opitz, C., Künzel, S.R., Michen, S., Temme, A., Loureiro, L.R., Feldmann, A., Bachmann, M., Boissel, L., Klingemann, H., Wels, W.S. ORCID: https://orcid.org/0000-0001-9858-3643 and Tonn, T. ORCID: https://orcid.org/0000-0001-9580-2193
Journal for ImmunoTherapy of Cancer 12 (2): e008155. 27 February 2024

2023

Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda et al.
Immisch, L. ORCID: https://orcid.org/0000-0001-5072-8583, Papafotiou, G., Popp, O. ORCID: https://orcid.org/0000-0001-6240-4666, Mertins, P. ORCID: https://orcid.org/0000-0002-2245-528X, Blankenstein, T. ORCID: https://orcid.org/0000-0002-3357-4321 and Willimsky, G. ORCID: https://orcid.org/0000-0002-9693-948X
Journal for ImmunoTherapy of Cancer 11 (3): e006784. 14 March 2023

Generation of TGFβR2(-1) neoantigen-specific HLA-DR4-restricted T cell receptors for cancer therapy.
Plewa, N. ORCID: https://orcid.org/0000-0002-5888-297X, Poncette, L. ORCID: https://orcid.org/0000-0001-8300-3968 and Blankenstein, T. ORCID: https://orcid.org/0000-0002-3357-4321
Journal for ImmunoTherapy of Cancer 11 (2): e006001. February 2023

2022

TIGIT blockade repolarizes AML-associated TIGIT(+) M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis.
Brauneck, F. ORCID: https://orcid.org/0000-0002-0026-3658, Fischer, B., Witt, M., Muschhammer, J., Oelrich, J., da Costa Avelar, P.H. ORCID: https://orcid.org/0000-0002-0347-7002, Tsoka, S., Bullinger, L. ORCID: https://orcid.org/0000-0002-5890-5510, Seubert, E., Smit, D.J. ORCID: https://orcid.org/0000-0002-3190-9511, Bokemeyer, C., Ackermann, C., Wellbrock, J., Haag, F. and Fiedler, W.
Journal for ImmunoTherapy of Cancer 10 (12): e004794. 22 December 2022

H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2(+) patients with diffuse midline glioma.
Immisch, L., Papafotiou, G., Popp, O. ORCID: https://orcid.org/0000-0001-6240-4666, Mertins, P. ORCID: https://orcid.org/0000-0002-2245-528X, Blankenstein, T. ORCID: https://orcid.org/0000-0002-3357-4321 and Willimsky, G. ORCID: https://orcid.org/0000-0002-9693-948X
Journal for ImmunoTherapy of Cancer 10 (10): e005535. 27 October 2022

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL.
Rejeski, K. ORCID: https://orcid.org/0000-0003-3905-0251, Perez, A., Iacoboni, G., Penack, O., Bücklein, V., Jentzsch, L., Mougiakakos, D., Johnson, G., Arciola, B., Carpio, C., Blumenberg, V., Hoster, E., Bullinger, L. ORCID: https://orcid.org/0000-0002-5890-5510, Locke, F.L., von Bergwelt-Baildon, M., Mackensen, A., Bethge, W., Barba, P., Jain, M.D. ORCID: https://orcid.org/0000-0002-7789-1257 and Subklewe, M.
Journal for ImmunoTherapy of Cancer 10 (5): e004475. 17 May 2022

Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside?
Guedan, S., Luu, M., Ammar, D., Barbao, P., Bonini, C., Bousso, P., Buchholz, C.J., Casucci, M., De Angelis, B. ORCID: https://orcid.org/0000-0002-7938-737X, Donnadieu, E. ORCID: https://orcid.org/0000-0002-4985-7254, Espie, D., Greco, B., Groen, R., Huppa, J.B. ORCID: https://orcid.org/0000-0003-2634-8198, Kantari-Mimoun, C., Laugel, B., Mantock, M., Markman, J.L., Morris, E., Quintarelli, C. ORCID: https://orcid.org/0000-0002-4343-9705, Rade, M., Reiche, K., Rodriguez-Garcia, A., Rodriguez-Madoz, J.R., Ruggiero, E., Themeli, M., Hudecek, M. and Marchiq, I.
Journal for ImmunoTherapy of Cancer 10 (5): e003487. May 2022

2021

Acute kidney injury in patients treated with immune checkpoint inhibitors.
Gupta, S. ORCID: https://orcid.org/0000-0002-5747-2151, Short, S.A.P., Sise, M.E., Prosek, J.M., Madhavan, S.M., Soler, M.J., Ostermann, M., Herrmann, S.M., Abudayyeh, A., Anand, S., Glezerman, I., Motwani, S.S., Murakami, N., Wanchoo, R., Ortiz-Melo, D.I., Rashidi, A., Sprangers, B., Aggarwal, V., Malik, A.B., Loew, S., Carlos, C.A., Chang, W.T., Beckerman, P., Mithani, Z., Shah, C.V., Renaghan, A.D., Seigneux, S.D., Campedel, L., Kitchlu, A. ORCID: https://orcid.org/0000-0002-4340-5046, Shin, D.S., Rangarajan, S., Deshpande, P., Coppock, G., Eijgelsheim, M., Seethapathy, H., Lee, M.D. ORCID: https://orcid.org/0000-0002-6895-5968, Strohbehn, I.A., Owen, D.H., Husain, M., Garcia-Carro, C., Bermejo, S., Lumlertgul, N., Seylanova, N., Flanders, L., Isik, B., Mamlouk, O. ORCID: https://orcid.org/0000-0002-1242-2740, Lin, J.S. ORCID: https://orcid.org/0000-0002-7073-9658, Garcia, P., Kaghazchi, A., Khanin, Y., Kansal, S.K., Wauters, E., Chandra, S., Schmidt-Ott, K.M. ORCID: https://orcid.org/0000-0002-7700-7142, Hsu, R.K., Tio, M.C., Sarvode Mothi, S., Singh, H., Schrag, D., Jhaveri, K.D., Reynolds, K.L., Cortazar, F.B. and Leaf, D.E. ORCID: https://orcid.org/0000-0001-7875-090X
Journal for ImmunoTherapy of Cancer 9 (10): e003467. October 2021

High-affinity T-cell receptor specific for MyD88 L265P mutation for adoptive T-cell therapy of B-cell malignancies.
Çınar, Ö. ORCID: https://orcid.org/0000-0001-5297-127X, Brzezicha, B., Grunert, C. ORCID: https://orcid.org/0000-0001-8376-8629, Kloetzel, P.M., Beier, C., Peuker, C.A. ORCID: https://orcid.org/0000-0002-0957-2166, Keller, U. ORCID: https://orcid.org/0000-0002-8485-1958, Pezzutto, A. ORCID: https://orcid.org/0000-0002-3246-4470 and Busse, A. ORCID: https://orcid.org/0000-0002-3470-6947
Journal for ImmunoTherapy of Cancer 9 (7): e002410. 30 July 2021